AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

AstraZeneca may have exited the COVID-19 vaccine ... claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). The AI effect in pharma commercial ...

Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

At an event held in the House of Lords on 5th November, The Trade Facilitation Commission released their detailed report and ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Kamala Harris lost 2024 US election, 10 large-cap stocks performed poorly: Moderna, Honda, Akamai, ADS, AstraZeneca, ...